Answers are grounded in this paper and cite their sources.
To the Editor: The term mild cognitive impairment (MCI) is generally used to refer to a transitional zone between normal cognitive function and mild dementia.1,2 For the progression from MCI to dementia, rates between 7% and 20% per year and up to 45% within 3 years have been reported.3–6 Our aim was to determine the outcome in patients diagnosed with MCI between 1994 and 2003 at the outpatient unit for cognitive disorders of the Technical University of Munich. Inclusionary criteria were aged 55 and older; impairment in at least one cognitive domain (memory, language, attention, or visuospatial processing); preserved activities of daily living (ADLs) according to an informant report; Clinical Dementia Rating (CDR) score of 0.5 (questionable dementia); no dementia according to International Classification of Diseases, 10th Revision, (ICD-10) criteria; and no somatic, neurological, or psychiatric illnesses that could cause cognitive deterioration. The diagnostic procedure at baseline and the personal follow-up examinations included history taken from the patient and from an informant; medical, neurological, and psychiatric examination; global neurocognitive evaluation using the Mini-Mental State Examination (MMSE) or the neuropsychological battery of the Consortium to Establish a Registry for Alzheimer's Disease and the clock-drawing test; rating of the overall severity of cognitive deficits using the CDR; and laboratory screening and brain imaging (computed tomography or magnetic resonance imaging). The follow-up examination did not include brain imaging, and five patients were examined over the telephone using the German Telephone Modified MMSE and the Bayer ADL scale.7,8 MCI was diagnosed at follow-up examination if patients had impairment in at least one cognitive domain (memory, language, attention, or visuospatial processing); preserved ADLs; no dementia according to ICD-10 criteria; and a CDR score of 0.5. The diagnosis of dementia at follow-up was based on ICD-10 criteria. Of 172 MCI patients, 82 agreed to participate in a follow-up examination. Of these, 77 were examined in person, and five were examined over the telephone. The mean follow-up period±standard deviation was 3.54±2.25 years (range 0.7–10.4 years). There were no statistically significant differences in age and initial MMSE scores between patients who were followed up and those who were not. The age of the participants at baseline was 65.9±9.6, the initial MMSE score was 27.2±1.9, and the length of the follow-up interval was 3.5±2.3 years. Within 3.2±2.2 years, 34 patients (41.5%) converted to dementia, whereas 48 (58.5%) did not progress to dementia over 3.5±2.3 years (34 stable MCI patients and 14 participants reverted to normal). The difference in the length of the follow-up period between the groups of the participants with the different outcomes was not statistically significant (analysis of variance, P=.07). The pairwise post hoc comparisons of the length of the follow-up intervals of the subjects who converted to dementia, those who were stable, and those who reverted to normal did not show any significant differences (Scheffe test, P=.79) (Figure 1). The participants who converted to dementia were significantly older than the other two groups, and their MMSE scores were significantly lower (analysis of variance, P<.05). Outcome in subjects diagnosed with mild cognitive impairment at baseline in correlation with the length of the follow-up period. These results confirm that the clinical syndrome of MCI has a variable prognosis. Seventeen percent of the MCI subjects returned to normal. Under the hypothesis that MCI is a predementia stage, this finding was unexpected. This study encompassed a broad definition of MCI, referring not only to memory deficits but also to impairments in other cognitive domains. The definition used in the present study resembles, in fact, the new recommendations for the general criteria for MCI.1 An explanation is that a subset of MCI patients may have a fundamentally different response to the process that in others rapidly evolves to dementia (resistance to disease or a better ability to compensate for deficits). The patients who progressed to dementia were older, and their initial MMSE scores were lower. This is consistent with data that the higher the severity of cognitive deficits at baseline, the higher the progression to dementia9 and that the incidence and prevalence of dementia increase with age.10 In conclusion, despite the commonly accepted hypothesis of MCI as a prodromal stage of dementia, a large proportion of the MCI patients on our outpatient unit remained stable or reverted to normal. These findings imply that MCI is a clinical syndrome with a highly variable prognosis. Financial Disclosure: Alexander Kurz received speaker and consultancy honoraria from AstraZeneca, Eisai, GlaxoSmithKline, Janssen-Cilag, Novartis, and Pfizer.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: